Alentis Therapeutics

Alentis has developed ALE.P02 and ALE.P03, antibody-drug conjugates designed for Claudin-1-positive solid tumors.

Alentis is developing lixudebart with CSL for rare kidney and liver diseases, including ANCA-associated vasculitis, focal segmental glomerulosclerosis and primary sclerosing cholangitis.

Alentis develops anti-Claudin-1 antibodies and antibody-drug conjugates for organ fibrosis and Claudin-1-positive tumors.

The page features updates on ALE.P02’s FDA Fast Track designation, Alentis’ Series D financing, a 2023 company event and ALE.F02 data.

The page lists Claudin-1 research publications in journals including Nature Reviews Cancer, Journal of Hepatology and Nephron.

Alentis Therapeutics founder Prof. Thomas Baumert received the Mémain-Pelletier award from the French Academy of Science for research into the pathogenesis of liver cancer.

ALENTIS Therapeutics announced a CHF 12.5 million Series A financing to develop therapeutics for advanced liver disease and cancer.

Alentis Therapeutics named Dr. Roberto Iacone as CEO. Iacone is a physician-scientist and entrepreneur with more than 15 years of life sciences industry experience.

Alentis Therapeutics raised USD67 (CHF60) million in a Series B financing round to fund proof-of-concept clinical trials of Claudin-1-targeting anti-fibrotic molecules in advanced liver and kidney fibrosis and support ongoing drug discovery.

Alentis is a biotech company developing medicines for cancer and fibrosis and seeks talent across healthcare, life science and pharmaceutical fields.

Alentis Therapeutics appointed Rizwan Velji as chief business officer to lead corporate strategy and business development. He has more than 20 years of experience in biotech financial services.

Luca Santarelli has more than 20 years of experience in academic and pharmaceutical R&D. He founded and led VectivBio AG, which was acquired by Ironwood Pharmaceuticals.

David Jayne is a professor of Clinical Autoimmunity at the University of Cambridge and director of the Vasculitis and Lupus Service at Addenbrooke’s Hospital.

Mark Pruzanski joined Alentis in 2025 as CEO. He is a physician and entrepreneur with more than 30 years of life sciences experience and previously served as chairman and CEO of Versanis Bio.

Alentis Therapeutics develops anti-Claudin-1 therapies for cancer and fibrosis.

Alentis is a clinical-stage biotech company developing anti-Claudin-1 antibody-drug conjugates and monoclonal antibodies for cancer and fibrosis.

Alentis Therapeutics AG operates the website, and its cookie statement explains the use of cookies and refers readers to its privacy statement.

Alentis Therapeutics’ privacy statement explains how the company handles personal data.

Alentis Therapeutics is developing treatments for Claudin-1-positive tumors and organ fibrosis. The page says clinical trials are the primary route to access its treatments until regulatory approval.